Peritoneal cancer treatment

Yonemura, Yutaka; Canbay, Emel; Endou, Yoshio; Ishibashi, Hiroyuki; Mizumoto, Akiyoshi; Miura, Masahiro; Li, Yan; Liu, Yan; Takeshita, Kazuyoshi; Ichinose, Masumi; Takao, Nobuyuki; Hirano, Masamitsu; Sako, Shouzou; Tsukiyama, Gorou

doi:10.1517/14656566.2014.879571

Cited by 45 publications

(28 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperative Grade 3, 4 and 5 complications after CRS were found in 12 (14.0%), 7 (8.1%), and 1 (1.2%) patient, respectively, which is even less than that found after CRS with or without Original Article from PSOGI Congress HIPAEC, 20,21 There was no patient who could not undergo CRS because of morbidity associated with NLHIPEC+NIPS. These results indicate that NLHIPEC+NIPS in combination with CRS can be safely performed with acceptable mortality and morbidity.…”

Section: Discussionmentioning

confidence: 82%

Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion and intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer

Yonemura¹,

Canbay

Fujita

et al. 2017

J Peritoneum

Self Cite

View full text Add to dashboard Cite

Our aim was to clarify the effects of neoadjuvant hyperthermic intraperitoneal chemoperfusion (NLHIPEC) followed by intraperitoneal/systemic chemotherapy (NIPS) on peritoneal metastasis from gastric cancer.After carrying out exploratory laparoscopy to determine the peritoneal cancer index (pretreatment PCI: Pre-PCI) in 150 patients, we performed NLHIPEC for 60 min. with peritoneal port placement: a series of 3-week cycles of NIPS using S1, docetaxel, and cisplatin two weeks after NLHIPEC: performed cytoreductive surgery in 86 patients four weeks after NIPS, and subsequently measured PCI (Post-PCI).Positive cytology in 38 patients changed to negative in 26 (68.4%) patients at laparotomy. The post-PCI (6.7 ± 7.8) was significantly lower than the pre-PCI (10.6± 10.2) (P=0.0001). The PCI was ≥14 in 30 patients at pretreatment and ≤ 13 in 19 (63.3 ) of these patients at posttreatmjent. Post-PCI cut-off level (≤ 13 vs ≥14) and cytology after NIPS (negative vs positive) emerged as independent indicators of prognosis. Postoperative mortality was 1.2% (1/86).NLHIPEC and NIPS are safe and effective modalities for reducing Post-PCI below the cut-off level and eradicating peritoneal free cancer cells.

show abstract

Section: Discussionmentioning

confidence: 82%

Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion and intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer

Yonemura¹,

Canbay

Fujita

et al. 2017

J Peritoneum

Self Cite

View full text Add to dashboard Cite

show abstract

“…The combined treatment of PC with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provides impressive results in patients with PC and has increased chances of patient survival [28, 29]. However, this is a rigorous surgical treatment that carries morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

“…The anti-EpCAM CAR sequence was designed by in silico assembly of fragments encoding the single-chain variable fragment (scFv) from 4D5MOC-B humanized mAb [28], the CD8 alpha hinge and transmembrane domain (uniprot P01732, residues 128-210), CD28 co-stimulatory domain (uniprot P10747, residues 180–220), 4-1BB co-stimulatory domain (uniprot Q07011, residues 214–255), and the CD3zeta intracellular ITAM domain (uniprot P20963,residues 52–164), followed by synthesis of the codon-optimized fusion gene (AIT Biotech, Singapore). The complete anti-EpCAM CAR sequence was inserted into the third generation self-inactivating lentiviral expression vector (CD810A-1; System Biosciences, Mountain View, CA) after EcoRI and SalI digestion.…”

Section: Methodsmentioning

confidence: 99%

Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis

Ang

Chi

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The epithelial cell adhesion molecule (EpCAM) is overexpressed in a wide variety of tumor types, including peritoneal carcinomatosis (PC) from gastrointestinal and gynecological malignancies. To develop a chimeric antigen receptor T (CART) cell therapy approach to treat patients with end-stage PC, we constructed third generation CARs specific to EpCAM using the 4D5MOC-B single chain variable fragment. CART cells were generated with lentiviral transduction and exhibited specific in vitro killing activity against EpCAM-positive human ovarian and colorectal cancer cells. A single intraperitoneal injection of the CART cells eradicated established ovarian xenografts and resulted in significantly prolonged animal survival. Since EpCAM is also expressed on normal epithelium, anti-EpCAM CART cells were generated by mRNA electroporation that display a controlled cytolytic activity with a limited CAR expression duration. Multiple repeated infusions of these RNA CAR-modified T cells delayed disease progression in immunodeficient mice bearing well-established peritoneal ovarian and colorectal xenografts. Thus, our study demonstrates the effectiveness of using anti-EpCAM CAR-expressing T cells for local treatment of PC in mice. The possibility of using this approach for clinical treatment of EpCAM-positive gastrointestinal and gynecological malignancies warrants further validation.

show abstract

“…The mixture was given orally 2 h before surgery. After oral administration, patients were kept away from direct sunlight for 24 h. After laparotomy, standard evaluation of the distribution and size of PM was conducted under white light, and peritoneal cancer index was calculated [27,28]. Tumor tissues and normal peritoneum were discriminated under white light.…”

Section: Clinical Application Of Ala Pdd To Detect Peritoneal Metamentioning

confidence: 99%

Photodynamic Detection of Peritoneal Metastases Using 5-Aminolevulinic Acid (ALA)

Yonemura

Endo

Canbay³

et al. 2017

Cancers

Self Cite

View full text Add to dashboard Cite

In the past, peritoneal metastasis (PM) was considered as a terminal stage of cancer. From the early 1990s, however, a new comprehensive treatment consisting of cytoreductive surgery and perioperative chemotherapy has been established to improve long-term survival for selected patients with PM. Among prognostic indicators after the treatment, completeness of cytoreduction is the most independent predictors of survival. However, peritoneal recurrence is a main cause of recurrence, even after complete cytoreduction. As a cause of peritoneal recurrence, small PM may be overlooked at the time of cytoreductive surgery (CRS), therefore, development of a new method to detect small PM is desired. Recently, photodynamic diagnosis (PDD) was developed for detection of PM. The objectives of this review were to evaluate whether PDD using 5-aminolevulinic acid (ALA) could improve detection of small PM.

show abstract

Peritoneal cancer treatment

Cited by 45 publications

References 76 publications

Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion and intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer

Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion and intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer

Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis

Photodynamic Detection of Peritoneal Metastases Using 5-Aminolevulinic Acid (ALA)

Contact Info

Product

Resources

About